Use of sodium-glucose cotransporter-2 inhibitors among Aboriginal people with type 2 diabetes in remote Northern Territory: 2012 to 2020

Matthew J L Hare; Winnie Chen; Thomas Berhane; Sumaria M Corpus; Louise J Maple-Brown

doi:10.1111/imj.16653

Use of sodium-glucose cotransporter-2 inhibitors among Aboriginal people with type 2 diabetes in remote Northern Territory: 2012 to 2020

Intern Med J. 2025 Mar;55(3):518-522. doi: 10.1111/imj.16653. Epub 2025 Feb 24.

Authors

Matthew J L Hare^{1

2}, Winnie Chen^{2

3}, Thomas Berhane⁴, Sumaria M Corpus^{1

5}, Louise J Maple-Brown^{1

2}

Affiliations

¹ Endocrinology Department, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
² Wellbeing and Chronic Preventable Diseases Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
³ Danila Dilba Health Service, Darwin, Northern Territory, Australia.
⁴ Division of Medicine, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
⁵ Aboriginal & Torres Strait Islander Advisory Group, Diabetes across the Lifecourse: Northern Australia Partnership, Menzies School of Health Research, Darwin, Northern Territory, Australia.

Abstract

Aboriginal people in remote Northern Territory communities experience the highest burden of type 2 diabetes (T2D) globally. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiac and renal outcomes in selected populations. However, safety in this context is unknown. We investigated SGLT2i use and outcomes in remote Aboriginal people with T2D between 2012 and 2020.

Keywords: general practice; indigenous health; pharmacoepidemiology; primary care; rural health service; type 2 diabetes.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Australian Aboriginal and Torres Strait Islander Peoples
Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / ethnology
Female
Humans
Male
Middle Aged
Northern Territory / epidemiology
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors

Abstract

Publication types

MeSH terms

Substances

Grants and funding